The agonizing itching is one of the most difficult symptoms to bear in patients with primary biliary cholangitis (PBC). It can have a far greater impact on everyday life, sleep and mental stability than the laboratory values of the underlying disease. New studies and congress papers from 2025 show that the therapeutic spectrum has expanded significantly in recent years. The focus today is on the targeted modulation of cholestatic mechanisms, in particular through inhibitors of bile acid transport and PPAR agonists, which not only have a favorable effect on the course of the disease but also on the symptom burden.
Autoren
- Tanja Schliebe
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Hereditary Transthyretin Amyloidosis with Polyneuropathy
New Treatment Options for ATTRv-PN
- Type 1 Diabetes: A New Disease-Modifying Treatment Approach
Slowing the loss of β-cell function and delaying the progression of the disease
- Liver Cancer
Artificial Intelligence in Precision Oncology—Opportunities and Challenges
- Acute nonspecific back pain
Implementing a biopsychosocial approach
- Psychedelic-assisted therapy
Current status of PAT
- Neuropathic Pain
Evidence-Based Neuromodulation Based on Clinical Trials and Real-World Data
- Fibromyalgia Syndrome
Development, Diagnosis, Epidemiology, and Treatment of a Disease Entity
- Juvenile Idiopathic Arthritis